Bacteriomimetic Liposomes Improve Antibiotic Activity of a Novel Energy-Coupling Factor Transporter Inhibitor.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Hirsch, Anna K H
MetadataShow full item record
AbstractLiposomes have been studied for decades as nanoparticulate drug delivery systems for cytostatics, and more recently, for antibiotics. Such nanoantibiotics show improved antibacterial efficacy compared to the free drug and can be effective despite bacterial recalcitrance. In this work, we present a loading method of bacteriomimetic liposomes for a novel, hydrophobic compound (HIPS5031) inhibiting energy-coupling factor transporters (ECF transporters), an underexplored antimicrobial target. The liposomes were composed of DOPG (18:1 (Δ9-cis) phosphatidylglycerol) and CL (cardiolipin), resembling the cell membrane of Gram-positive Staphylococcus aureus and Streptococcus pneumoniae, and enriched with cholesterol (Chol). The size and polydispersity of the DOPG/CL/± Chol liposomes remained stable over 8 weeks when stored at 4 °C. Loading of the ECF transporter inhibitor was achieved by thin film hydration and led to a high encapsulation efficiency of 33.19% ± 9.5% into the DOPG/CL/Chol liposomes compared to the phosphatidylcholine liposomes (DMPC/DPPC). Bacterial growth inhibition assays on the model organism Bacillus subtilis revealed liposomal HIPS5031 as superior to the free drug, showing a 3.5-fold reduction in CFU/mL at a concentration of 9.64 µM. Liposomal HIPS5031 was also shown to reduce B. subtilis biofilm. Our findings present an explorative basis for bacteriomimetic liposomes as a strategy against drug-resistant pathogens by surpassing the drug-formulation barriers of innovative, yet unfavorably hydrophobic, antibiotics.
CitationPharmaceutics. 2021 Dec 21;14(1):4. doi: 10.3390/pharmaceutics14010004.
AffiliationHIRI, Helmholtz-Institut für RNA-basierte Infektionsforschung, Josef-Shneider Strasse 2, 97080 Würzburg, Germany.
The following license files are associated with this item:
- Creative Commons
- Antimicrobial effectiveness of liposomal polymyxin B against resistant Gram-negative bacterial strains.
- Authors: Alipour M, Halwani M, Omri A, Suntres ZE
- Issue date: 2008 May 1
- DMPC/Chol liposomal copper CX5461 is therapeutically superior to a DSPC/Chol formulation.
- Authors: Leung AWY, Chen KTJ, Ryan GM, Anantha M, Wretham N, Nosrati Z, Heroux D, Wang L, Chow N, Dai Z, Bally MB
- Issue date: 2022 Mar 5
- Tamoxifen in topical liposomes: development, characterization and in-vitro evaluation.
- Authors: Bhatia A, Kumar R, Katare OP
- Issue date: 2004 Jul 16
- A Study of Liposomal Formulations to Improve the Delivery of Aquated Cisplatin to a Multidrug Resistant Tumor.
- Authors: Zhao Y, May JP, Chen IW, Undzys E, Li SD
- Issue date: 2015 Oct
- Novel formulation of antimicrobial peptides enhances antimicrobial activity against methicillin-resistant Staphylococcus aureus (MRSA).
- Authors: Faya M, Hazzah HA, Omolo CA, Agrawal N, Maji R, Walvekar P, Mocktar C, Nkambule B, Rambharose S, Albericio F, de la Torre BG, Govender T
- Issue date: 2020 Oct